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Abstract
Background: Information on hemostasis and platelet function in brown bear (Ursus arctos) is of importance for 
understanding the physiological, protective changes during hibernation.
Objective: The study objective was to document platelet activity values in brown bears shortly after leaving the den 
and compare them to platelet function in healthy humans.
Methods: Blood was drawn from immobilized wild brown bears 7-10 days after leaving the den in mid April. Blood 
samples from healthy human adults before and after clopidogrel and acetylsalicylic acid administration served as 
control. We analyzed blood samples by standard blood testing and platelet aggregation was quantified after 
stimulation with various agonists using multiple electrode aggregometry within 3 hours of sampling.
Results: Blood samples were collected from 6 bears (3 females) between 1 and 16 years old and from 10 healthy 
humans. Results of adenosine diphosphate, aspirin, and thrombin receptor activating peptide tests in bears were all 
half or less of those in humans. Platelet and white blood cell counts did not differ between species but brown bears 
had more and smaller red blood cells compared with humans.
Conclusion: Using three different tests, we conclude that platelet function is lower in brown bears compared to 
humans. Our findings represent the first descriptive study on platelet function in brown bears and may contribute to 
explain how bears can endure denning without obvious thrombus building. However, the possibility that our findings 
reflect test-dependent and not true biological variations in platelet reactivity needs further studies.
Introduction
Hibernating Scandinavian brown bears (Ursus arctos)
stay inside their winter dens for approximately 5-7
months [1,2] and during this hibernation period they do
not eat, drink, defecate, urinate or have any physical
activity. Despite this, brown bears do not develop deteri-
oration in heart function [3], muscle atrophy [4], osteo-
porosis (black bear, Ursus americanus, observation [5]),
or decubitus ulcer (authors observation). Immobility pre-
disposes humans to thromboembolism [6] but in accor-
dance with findings in other hibernating animals [7] it is
unlikely that denning bears develop coagulation distur-
bances. In contrast to most other hibernating animals,
the brown bear sustains a body temperature (31-35°C)
near normal during hibernation [8-10]. How the brown
bear tolerates the physiological extremes related to hiber-
nation is unknown.
Information on the coagulation system in bears is
scarce. Previous studies have studied haptoglobin and α2-
macroglobulin and found both parameters to rise in
brown and black bears (Ursus americanus) during hiber-
nation as compared to the active state [8,9,11,12]. We
believe that the hibernating brown bear can act as a bio-
logical model for insight into the mechanisms of cardio-
vascular disease in humans. Because physical inactivity
and lying flat on the ground are thrombogenic and
because the brown bear apparently is free from throm-
boembolic events we hypothesized that brown bears
would demonstrate low platelet activity shortly after leav-
ing the den. In order to characterise the physiological
impact we compared our findings to human platelet func-
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Material
In mid-April 2009, approximately 7-10 days after leaving
the den, wild brown bears were immobilized from a heli-
copter by darting with a mixture of tiletamine-zolazepam
and medetomidine [13]. Blood was drawn from the jugu-
lar vein in accordance with previous reports [14]. The
study of bears was approved by the Swedish Ethical Com-
mittee on animal research
Blood samples from healthy human adult volunteers
were collected from the antecubital vein. None of the vol-
unteers were taking any regular medication and none had
ingested acetylsalicylic acid for at least a week before
blood sampling. Blood was drawn before and 24 hours
after an oral loading dose of 600 mg of clopidogrel and,
following at least a 10-day interim period, before and 24
hours after an oral loading dose of 600 mg of acetylsali-
cylic acid. The study done of humans was approved by
the regional ethical committee and each subject gave
written informed consent.
Routine blood cell count
Automated blood count was carried out using flow
cytometry (XE-5000, Sysmex Corporation, Kobe, Japan).
Platelet aggregometry
Whole blood was drawn into 3 ml plastic syringes con-
taining lepirudin (25 μg/ml, Refludan, hirudin blood col-
lection tubes, Dynabyte, München, Germany) and
analyzed by multiple electrode platelet aggregometry
between 0.5 and 3 hours after sampling. Electrical
aggregometry measures the increase in impedance
between a pair of metal electrodes immersed in diluted
whole blood. The increase in impedance correlates with
the amount of platelets aggregating on the electrodes
after adding a platelet agonist to the diluted whole blood.
The method correlates well with light transmission
aggregometry [15]. Multiple electrode aggregometry was
performed at 37°C with a constant stir bar speed of 1000
rpm on a multiple platelet function analyzer (Multiplate
impedance aggregometer, Dynabyte). In a polycarbonate
cuvette 300 μL of 0.9% NaCl and 300 μL of whole blood
were incubated for three minutes before 20 μL of the ago-
nist was added. Aggregation was started by adding ade-
nosine diphosphate (ADP) to obtain a concentration of
6.4 μmol/L, arachidonic acid (ASPI-test) to obtain a con-
centration of 0.5 mM or thrombin receptor activating
peptide (TRAP) to obtain a concentration of 32 μM.
Platelet aggregation expressed as increase in impedance
(W) was continuously recorded for 6 minutes. Imped-
ance, and thus aggregation is quantified as arbitrary
aggregation units (AU) after 6 minutes and the area
under the curve of arbitrary units (AUC).
Statistics
Values are presented as mean ± standard error of the
mean (SEM). The Holm-Sidak one-way analysis of vari-
ance (ANOVA) multiple comparisons test was used for
pairwise comparisons between bears and humans (base-
line, acetylsalicylic acid and clopidogrel). Bivariate associ-
ations were examined by least square linear regression.




Blood samples were collected from 6 brown bears (3
females) between 1 and 16 years old and from 10 healthy
human volunteers (3 females) between 28 and 58 years
old. The number of platelets and white blood cells did not
differ between species (Additional file 1; Table S1). Com-
pared with humans, brown bears had more and smaller
red blood cells with less haemoglobin per cell but with
more haemoglobin per volume unit of blood because of
the higher number of cells.
Platelet aggregometry
In humans, ADP stimulation (AU or AUC) was unaf-
fected by 300 mg of acetylsalicylic acid. Clopidogrel 600
mg, on the other hand, reduced both these numbers by
half compared to baseline and to a level almost equal to
the brown bear values (Figure 1, Additional file 2; Table
S2).
At baseline, results from stimulation with arachidonic
acid (ASPI-test) in humans were more than twice the val-
ues found in bears. A dramatic reduction in the ASPI-test
was seen in humans after acetylsalicylic acid and a mod-
est reduction was seen after clopidogrel (Additional file 2;
Table S2).
In humans, only minor non-statistically significant
changes in thrombin receptor activating peptide (TRAP)
testing were seen after acetylsalicylic acid and clopidogrel
and all values were 4-10 times higher than the brown bear
values (Additional file 2; Table S2).
There were no statistically significant correlation
between age of the bears and aggregometer testing
results. The highest r-value for linear regression was 0.27
(P = 0.60) between ADP aggregation units and age (the
other r-values were lower and are not shown).
Discussion
Our main findings on platelet function in Scandinavian
brown bears are that all the functional parameters of
platelets we investigated by multiple electrode aggregom-
etry were half or less of those of human values. Platelet
count did not differ between species.
Until now, information on brown bear coagulation and
platelet function has been limited. Two studies have
found that haptoglobin is higher in hibernating than non-
hibenating black [11] and brown bears [12]. Another
large plasma protein, α2-macroglobulin, increases clot-
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found to be significantly higher during hibernation com-
pared to the active state of brown bears [12] and black
bears [16], indicating anticoagulation during hibernation.
Current research on comparative hemostasis among
species is increasing but for most animals not routinely
used in laboratory research this area remains scarcely
covered, primarily because of the lack of species-specific
antibodies for immunological assays [17]. Older studies
have even suggested that quantitative comparisons
between hemostasis in different species are illusory,
because any difference found will have qualitative and
quantitative aspects [18]. A more recent commentary put
forward that the basis of blood coagulation in vertebrates
involves tissue factor and fibrinogen developed from a
primordial system, with all the other factors "sandwiched"
in later during evolution [19]. Because the main goal of
aggregation is the binding of fibrinogen to the platelet
receptor glycoprotein IIb-IIIa, this hypothesis opens for
functional testing of platelet aggregatory responses to
agonists in vitro in most species. Everything boils down
to formation of the thrombus and, given that relevant
agonists are used, between-species comparisons can be
made - for example by aggregometer testing. In a com-
parative aggregometer study comparing human, dog and
calf blood, the authors concluded that ADP and collagen
are the agonists of choice giving the most consistent
results between species [20]. A recent study using
aggregometer testing in llamas (Lama glama) demon-
strated that platelets from this animal were responsive to
ADP but unresponsive to arachidonic acid [21].
Our aggregometer findings in bears were consistent; all
bears demonstrated lower platelet function values than in
humans. Adenosine diphosphate, aspirin and thrombin
receptor activating peptide tests were all statistically sig-
nificantly lower in bears and the test values were compa-
rable to values obtained in humans following platelet
inhibition with clopidogrel or acetylsalicylic acid admin-
istration in this study and as demonstrated by others [22].
In our small material, there was no apparent systematic
difference in platelet function between adult bears and
yearlings or between sexes. All our samples were taken in
mid April and must be considered as a snapshot of plate-
let function. Therefore we cannot comment on whether
platelet function changes during denning but any possible
hibernation effect might still be present in our material,
because sampling was conducted so soon after leaving
the den.
The physiological significance of our findings could be
straightforward; the apparently low platelet aggregation
in brown bears might help them to sustain 6 months of
winter sleep lying on the ground with limited physical
activity obviously without significant thromboembolic
events. The platelet number in bear blood (demonstrat-
ing values within the human range) and functional testing
with three different agonists using platelet aggregometer
(with consistently lower values compared with humans)
could indicate spontaneous reduced platelet function in
brown bears compared to humans. However, the possibil-
ity that our findings reflect test-dependent and not true
biological variations in platelet reactivity needs further
studies.
A potential source of error in our assessment of platelet
function in brown bears is the effect of the anaesthetics
used. The alpha-2 agonist medetomidine does not alter
platelet aggregation [23] while no studies are available for
the tiletamine-zolazapam combination on coagulation
and platelet activation. However, higher cardiac and
stroke indices have been observed in rats with tiletamine-
zolazapam than with ketamine and pentobarbital [24].
For xylazine-tiletamine-zolazapam one study on horses
found a reduction in platelet count after 10 minutes that
returned to normal within 30-60 minutes whereas a xyla-
zine-diazepam-ketamine combination resulted in an
Figure 1 Traces of platelet function analyzer testing following adenosine diphosphate stimulation in a 4-year old male brown bear (left) 
and in a 58-year old healthy female volunteer before and after the administration of 300 mg of acetylsalicylic acid (ASA) and 600 mg of 
clopidogrel. Platelet aggregation is expressed as increase in impedance after 6 minutes quantified as arbitrary aggregation units (AU). The mean of 
two runs (red and blue curves) was used. Please note different scaling.
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data we find it reasonable to conclude that titelamine-
zolazapam in combination with medetomidine most
likely had a neutral effect on platelet aggregation
A limitation of our study was that we did not measure
specific clotting factors or complementary characterisa-
tion of platelet function in order to characterize what
specific part of aggregation is inhibited in bears. By per-
forming all sampling at the same time of the year we pro-
vided a snapshot of platelet function that is not
generalizable to other times of the year - e.g. in autumn
following excessive intake of bilberries (Vaccinium myr-
tillus) and crowberries (Empetrum hermaphoditum)
(both might inhibit platelet function [26]) or while the
bears lie inactive in the den (theoretically predisposing
them to thromboembolism [6]). Also, we did not charac-
terize bear platelet ultrastructural anatomy. Our study
was conducted to test biological relevance and feasibility
and fieldwork logistics in order to formulate an ade-
quately substantiated application for ethical approval to
perform research on hibernating brown bears. Recently
this ethical approval was granted to us and we hope in the
future to be able to present data on platelet function in
the same bears in hibernation and in the active state.
We conclude that platelet function values using ADP,
ASPI or TRAP are lower in Scandinavian brown bears
than in humans. Our findings represent the first descrip-
tive study on platelet function in brown bears and may
reflect true biological variation, but test specific differ-
ences cannot be excluded. More studies are needed to
clarify whether these findings may contribute to explain
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